Conduct of Research Collaboration Sample Clauses

Conduct of Research Collaboration. During the term of the Research Collaboration, each party shall:
Sample 1Sample 2See All (6)
AutoNDA by SimpleDocs
Conduct of Research Collaboration. (i) On or about August 1, 2002, Gilead will, at its own expense, supply to Anadys the quantities of the Target set forth in the Work Plan and the Library Compounds, as selected by Gilead. Anadys will diligently use its screen development and assay validation capabilities to develop two (2) validated screening assays for use with ATLAS for the Target (each, a "TARGET ASSAY") pursuant to the Work Plan. One Target Assay will be for use with [...***...] and one Target Assay will be for use with no [...***...]. The Work Plan Sets forth guidance for other parameters and specifications for the Target Assays. Anadys will provide Gilead with monthly oral or written updates as to the progress of the Target Assay development, will consider in good faith any guidance or comments that Gilead provides with respect to such development, and, for any candidate Target Assay, will provide Gilead with a report on such assay, including relevant testing and validation results, sufficient for Gilead to evaluate such assay against the required parameters and specifications and Anadys's description of the assay. Gilead shall have the right to approve any candidate Target Assay, with such approval not to be unreasonably withheld. If Gilead does not approve a candidate Target Assay, the JRC will meet to determine in good faith what additional work, if any, must be performed to qualify an assay as a Target Assay and shall amend the Work Plan to include such additional work. Once Gilead has approved the Target Assays, the JRC will determine the Target Assay Criteria for each Target Assay, according to the guidelines set forth in the Work Plan. Based on the actual screening results, the JRC may adjust the Target Assay Criteria so that an appropriate number of Hit Compounds are generated from the screening.
Sample 1Sample 2
Conduct of Research Collaboration. 5.6 Visitation.................................................... 5.7
Sample 1
Conduct of Research Collaboration. Each Party: 3.6.1. shall use Commercially Reasonable Efforts to conduct its responsibilities under the Work Plan, as assigned to it under each Project Plan, and to achieve the objectives and timelines set forth in the Work Plan, provided that, should either Party foresee any material changes to the timelines or R&D Budget, such Party should promptly notify the other Party; 3.6.2. shall conduct its activities under the Research Collaboration in compliance with good scientific manner, pursuant to scientific standards and in compliance with this Agreement and all Applicable Laws; 3.6.3. shall ensure that its employees and contractors utilized in the activities under the Work Plan are qualified to perform those activities assigned to such Party under the Work Plan and applicable Project Plan; and 3.6.4. may utilize the services of its Affiliates (as further set forth in Section 16.3), Permitted Subcontractors and, in the case of MKDG, any Third Parties or Related Parties to perform those activities assigned to it under the Work Plan; provided that any such Party shall remain responsible for the performance of such Affiliates and Third Parties or Related Parties hereunder. 3.7.
Sample 1
Conduct of Research Collaboration. During the Collaboration Term and under the direction and supervision of the CMC, each Party shall (a) perform or cause to be performed its obligations under the Research Plan in good scientific manner and in compliance in all relevant material aspects with all Applicable Law, including, as required by the Research Plan, good laboratory practices, good manufacturing practice and good clinical practices, (b) allocate sufficient time, effort, equipment and skilled personnel to complete such activities successfully and promptly and (c) insofar as the activities involve the use of animals by Palatin, Palatin shall conduct activities in accordance with the AAALAC standards and AstraZeneca International Policy on Animal Care and Use, attached hereto as Schedule 3.1, to the extent stricter than the AAALAC standards. Following the Effective Date, the Parties shall promptly commence the Research Collaboration.
Sample 1
Conduct of Research Collaboration. During the Collaboration Term and under the direction and supervision of the RCMC, each Party shall (a) perform or cause to be performed its obligations under the Research Plan in good scientific manner and in compliance in all material aspects with all Applicable Law, including, unless otherwise set forth in the Research Plan, good laboratory practices and good clinical practices, and (b) allocate the time, effort, equipment and skilled personnel to complete such activities as set forth in the Research Plan. Following the Effective Date, the Parties shall promptly commence the Research Collaboration. Avanir undertakes insofar as it relates to animal care in the activities to be carried out by it hereunder to comply with the AAALAC standards and shall use its best reasonable efforts to comply with the AstraZeneca International Policy on Animal Care and Use to the extent stricter than the AAALAC standards.
Sample 1
Conduct of Research Collaboration. Except as contemplated by the Research Plan, the Research will be conducted by LKS at LKS's laboratories or such other sites approved by the CMC. LKS will use all commercially reasonable and diligent efforts to complete Research but in no event shall LKS be obligated to provide research funding or perform Research beyond that funded by RBS and/or as set forth in Section 5.7.2.
Sample 1
AutoNDA by SimpleDocs
Conduct of Research Collaboration 
Sample 1Sample 2Sample 3See All (5)

Related to Conduct of Research Collaboration

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Research Matters By entering into this Agreement, the Placement Agent does not provide any promise, either explicitly or implicitly, of favorable or continued research coverage of the Company and the Company hereby acknowledges and agrees that the Placement Agent’s selection as a placement agent for the Offering was in no way conditioned, explicitly or implicitly, on the Placement Agent providing favorable or any research coverage of the Company. In accordance with FINRA Rule 2711(e), the parties acknowledge and agree that the Placement Agent has not directly or indirectly offered favorable research, a specific rating or a specific price target, or threatened to change research, a rating or a price target, to the Company or inducement for the receipt of business or compensation.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

Time is Money Join Law Insider Premium to draft better contracts faster.